Overview

China Stroke Primary Prevention Trial for Subjects With Hypertension and MTHFR 677 TT Genotype (CSPPT2-TT)

Status:
Not yet recruiting

Trial end date:
2026-07-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, controlled clinical trial. It aims to investigate the treatment effects of amlodipine folic acid, and its combination of folic acid, compared to amlodipine, on reducing the risk of first ischemic stroke among those participants with the MTHFR 677 TT genotype and hypertension. This study consists of 3 phases: Screening, Run-in period (0 or 2 weeks), and randomized treatment (5 years), with a prospective, randomized, open-label, blinded end-point design.

Phase:

Phase 4

Details

Lead Sponsor:

Shenzhen Ausa Pharmed Co.,Ltd

Collaborators:

First Affiliated Hospital of Harbin Medical University
Peking University First Hospital
Second Affiliated Hospital of Nanchang University
Shenzhen CCHRPP Biomedical Institute
The First Affiliated Hospital of Shanxi Medical University
The First People's Hospital of Lianyungang

Treatments:

Amlodipine
Folic Acid
Vitamin B Complex